Innovating Works

Descin BV

A stranger
METHYLOMIC: DNA methylation markers to predict treatment success of biologicals in Crohn’s disease. DESCIN BV participó en un HORIZON EUROPE HORIZON-HLTH-2022-TOOL-11 Monoclonal antibodies have become a mainstay of therapy in common immune-mediated diseases (IMID) including Crohn’s disease (CD), rheumatoid...
2022-11-24 - 2026-12-31 | financed
TRAIN-HEART: TRAIN HEART DESCIN BV participó en un H2020 H2020-MSCA-ITN-2018 TRAIN-HEART brings together leading academic teams and (biotech) companies to train the next-generation of innovation-minded researchers who...
2019-04-08 - 2023-08-31 | financed
REPROGRAM: Targeting epigenetic REPROGRamming of innate immune cells in Atherosclerosis Management and other ch... DESCIN BV participó en un H2020 H2020-PHC-2014-2015 Up to 70% of cardiovascular events are not prevented by current therapeutic regimens. In search for additional, innovative strategies, immun...
2015-12-04 - 2019-12-31 | financed
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.